AU2009330245C1 - Novel antibacterial agents for the treatment of gram positive infections - Google Patents

Novel antibacterial agents for the treatment of gram positive infections Download PDF

Info

Publication number
AU2009330245C1
AU2009330245C1 AU2009330245A AU2009330245A AU2009330245C1 AU 2009330245 C1 AU2009330245 C1 AU 2009330245C1 AU 2009330245 A AU2009330245 A AU 2009330245A AU 2009330245 A AU2009330245 A AU 2009330245A AU 2009330245 C1 AU2009330245 C1 AU 2009330245C1
Authority
AU
Australia
Prior art keywords
compounds
compound
bacteria
clostridium difficile
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009330245A
Other languages
English (en)
Other versions
AU2009330245A1 (en
AU2009330245B2 (en
Inventor
Jing Li
Chester A. Metcalf Iii
Andre Lee Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2009330245A1 publication Critical patent/AU2009330245A1/en
Application granted granted Critical
Publication of AU2009330245B2 publication Critical patent/AU2009330245B2/en
Priority to AU2013209387A priority Critical patent/AU2013209387A1/en
Publication of AU2009330245C1 publication Critical patent/AU2009330245C1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request for Assignment Assignors: CUBIST PHARMACEUTICALS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009330245A 2008-12-22 2009-12-18 Novel antibacterial agents for the treatment of gram positive infections Ceased AU2009330245C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013209387A AU2013209387A1 (en) 2008-12-22 2013-07-29 Novel Antibacterial Agents for the Treatment of Gram Positive Infections

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13987508P 2008-12-22 2008-12-22
US61/139,875 2008-12-22
PCT/US2009/068747 WO2010075215A1 (en) 2008-12-22 2009-12-18 Novel antibacterial agents for the treatment of gram positive infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013209387A Division AU2013209387A1 (en) 2008-12-22 2013-07-29 Novel Antibacterial Agents for the Treatment of Gram Positive Infections

Publications (3)

Publication Number Publication Date
AU2009330245A1 AU2009330245A1 (en) 2011-08-04
AU2009330245B2 AU2009330245B2 (en) 2013-05-02
AU2009330245C1 true AU2009330245C1 (en) 2013-09-26

Family

ID=41718893

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009330245A Ceased AU2009330245C1 (en) 2008-12-22 2009-12-18 Novel antibacterial agents for the treatment of gram positive infections

Country Status (26)

Country Link
US (3) US8507647B2 (enExample)
EP (2) EP2674437A1 (enExample)
JP (1) JP5670914B2 (enExample)
KR (1) KR101717795B1 (enExample)
CN (1) CN102325787B (enExample)
AR (1) AR074833A1 (enExample)
AU (1) AU2009330245C1 (enExample)
BR (1) BRPI0923567A2 (enExample)
CA (1) CA2747965C (enExample)
CY (1) CY1114883T1 (enExample)
DK (1) DK2379580T3 (enExample)
ES (1) ES2442167T3 (enExample)
HR (1) HRP20131170T1 (enExample)
IL (1) IL213638A0 (enExample)
MX (1) MX2011006803A (enExample)
NZ (1) NZ594019A (enExample)
PL (1) PL2379580T3 (enExample)
PT (1) PT2379580E (enExample)
RS (1) RS53152B (enExample)
RU (1) RU2512396C2 (enExample)
SG (1) SG172299A1 (enExample)
SI (1) SI2379580T1 (enExample)
SM (1) SMT201400037B (enExample)
TW (1) TWI444198B (enExample)
WO (1) WO2010075215A1 (enExample)
ZA (1) ZA201104693B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013157188A (ru) 2011-05-26 2015-07-10 Кьюбист Фармасьютикалз, Инк. Композиции св-183,315 и относящиеся к ним способы
US10377699B2 (en) * 2013-11-06 2019-08-13 The University Of Hong Kong Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue
WO2015172047A1 (en) * 2014-05-08 2015-11-12 Merck Sharp & Dohme Corp. Cyclic peptide compounds and related methods, salts and compositions
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
MX386103B (es) * 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.
US10098890B2 (en) 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
IT201600127655A1 (it) * 2016-12-16 2018-06-16 Gnosis Spa Processo per la purificazione di antibiotici lipopolipeptidici
US10072045B1 (en) 2017-06-26 2018-09-11 Ramapo Pharmaceuticals, Inc. Antibacterial lipopeptides and methods for their preparation and use
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
RU2762182C1 (ru) * 2020-12-08 2021-12-16 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" Гауземицины А и В - гликолипопептидные антибактериальные антибиотики и способ их получения

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044272A2 (en) * 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Daptomycin analogs as antibacterial agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4812470A (en) 1982-02-27 1989-03-14 Beecham Group P.L.C. Antibacterial monic acid derivatives
US4399067A (en) 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4396543A (en) * 1982-05-21 1983-08-02 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
IL68700A0 (en) * 1982-05-21 1983-09-30 Lilly Co Eli Improvements relating to a-21978c cyclic peptide derivatives and their production
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CS276978B6 (en) 1984-10-09 1992-11-18 Lilly Co Eli Process for preparing a-21978c antibiotic derivative
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
CA2043762C (en) 1990-06-07 2001-05-29 Adam J. Kreuzman Lipopeptide deacylase
AU7497594A (en) 1993-08-13 1995-03-14 Smithkline Beecham Plc Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2248348C (en) 1996-03-08 2008-06-10 Fujisawa Pharmaceutical Co., Ltd. Process for the deacylation of cyclic lipopeptides
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
HK1040363B (en) 1998-09-25 2007-01-26 Cubist Pharmaceuticals Llc Use of daptomycin
JP2003520353A (ja) 1999-11-03 2003-07-02 ザ ウィタカー コーポレーション マルチファイバアレー用光電子モジュール
WO2001044271A2 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Daptomycin analogs and their use as antibacterial agents
KR20020063228A (ko) 1999-12-15 2002-08-01 큐비스트 파마슈티컬즈 인코포레이티드 항균제로서 리포펩티드
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1423137B1 (en) 2001-08-06 2009-04-29 Cubist Pharmaceuticals, Inc. Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
EP1814588A2 (en) * 2004-11-12 2007-08-08 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044272A2 (en) * 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Daptomycin analogs as antibacterial agents

Also Published As

Publication number Publication date
KR101717795B1 (ko) 2017-03-17
PT2379580E (pt) 2014-01-20
HRP20131170T1 (hr) 2014-01-03
JP2012513467A (ja) 2012-06-14
HK1161886A1 (en) 2012-08-10
SMT201400037B (it) 2014-05-07
EP2379580A1 (en) 2011-10-26
AR074833A1 (es) 2011-02-16
TW201028161A (en) 2010-08-01
EP2674437A1 (en) 2013-12-18
ZA201104693B (en) 2013-01-30
AU2009330245A1 (en) 2011-08-04
JP5670914B2 (ja) 2015-02-18
AU2009330245B2 (en) 2013-05-02
ES2442167T3 (es) 2014-02-10
NZ594019A (en) 2013-08-30
DK2379580T3 (da) 2014-01-20
SG172299A1 (en) 2011-07-28
WO2010075215A1 (en) 2010-07-01
CY1114883T1 (el) 2016-12-14
CN102325787A (zh) 2012-01-18
KR20110114592A (ko) 2011-10-19
PL2379580T3 (pl) 2014-05-30
CA2747965A1 (en) 2010-07-01
SI2379580T1 (sl) 2014-02-28
CN102325787B (zh) 2014-05-28
US20100184649A1 (en) 2010-07-22
CA2747965C (en) 2017-06-27
EP2379580B1 (en) 2013-10-23
RU2011130278A (ru) 2013-01-27
MX2011006803A (es) 2011-09-06
US20150337013A1 (en) 2015-11-26
US20140073558A1 (en) 2014-03-13
TWI444198B (zh) 2014-07-11
BRPI0923567A2 (pt) 2016-09-27
US8507647B2 (en) 2013-08-13
RS53152B (sr) 2014-06-30
RU2512396C2 (ru) 2014-04-10
IL213638A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
AU2009330245C1 (en) Novel antibacterial agents for the treatment of gram positive infections
US6794490B2 (en) Lipopeptides as antibacterial agents
AU784755B2 (en) Daptomycin Analogs as antibacterial agents
US20080287347A1 (en) Novel Lipopeptides as Antibacterial Agents
AU2013209387A1 (en) Novel Antibacterial Agents for the Treatment of Gram Positive Infections
HK1161886B (en) Novel antibacterial agents for the treatment of gram positive infections
HK1156040A (en) Lipopeptides as antibacterial agents

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 APR 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 APR 2013

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 NOV 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 NOV 2013

PC Assignment registered

Owner name: MERCK SHARP & DOHME CORP.

Free format text: FORMER OWNER WAS: CUBIST PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired